Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors

被引:7
作者
Collins, James C. [2 ]
Armstrong, Alan [2 ]
Chapman, Kathryn L. [1 ]
Cordingley, Hayley C. [1 ]
Jaxa-Chamiec, Albert A. [1 ]
Judd, Katie E. [1 ,2 ]
Mann, David J. [3 ]
Scott, Katherine A. [3 ]
Tralau-Stewart, Catherine J. [1 ]
Low, Caroline M. R. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Drug Discovery Ctr, Charing Cross Hosp, Rm 5L17,Lab Block,St Dunstans Rd, London W6 8RP, England
[2] Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England
[3] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England
关键词
DUAL-SPECIFICITY PHOSPHATASE; CELL-CYCLE PHOSPHATASE; PROTEIN PHOSPHATASE; CRYSTAL-STRUCTURE; CANCER-CELLS; MAP KINASE; VHR; TYROSINE; OVEREXPRESSION; DISCOVERY;
D O I
10.1039/c3md00047h
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of novel reversible inhibitors of the dual-specificity phosphatase Cdc25 was discovered using a two-stage molecular field-based similarity analysis. This method compares molecules on the basis of electrostatic and steric features, rather than their underlying structures, facilitating scaffold-hopping to new chemotypes. In this prospective study, a field point pharmacophore model was generated from three structurally diverse, reversible Cdc25 inhibitors and used in field-based virtual screening of 3.7 million commercially available compounds. Seven thiazoles, from the small set of 35 compounds selected for testing, showed reversible inhibition of activity at all three isoforms of Cdc25 (Cdc25A, B and C) at micromolar concentrations. The new series are not structurally related to the initial three starting points, but share their biological properties. Substructure searching rapidly identified additional thiazoles with modest (10-fold) increases in activity equivalent to those of the initial three starting points. This study demonstrates the effectiveness of this ligand-based method to both define a pharmacophore and effect virtual screening resulting in rapid and efficient identification of chemical starting points for development of novel therapeutic agents.
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 71 条
  • [11] Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design
    Bellenie, Benjamin R.
    Barton, Nicholas P.
    Emmons, Amanda J.
    Heer, Jag P.
    Salvagno, Cristian
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 990 - 994
  • [12] The when and wheres of CDC25 phosphatases
    Boutros, R
    Dozier, C
    Ducommun, B
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (02) : 185 - 191
  • [13] CDC25B involvement in the centrosome duplication cycle and in microtubule nucleation
    Boutros, Rose
    Lobjois, Valerie
    Ducommun, Bernard
    [J]. CANCER RESEARCH, 2007, 67 (24) : 11557 - 11564
  • [14] CDC25 phosphatases in cancer cells: key players? Good targets?
    Boutros, Rose
    Lobjois, Valerie
    Ducommun, Bernard
    [J]. NATURE REVIEWS CANCER, 2007, 7 (07) : 495 - 507
  • [15] IRC-083864, a novel his quinone inhibitor of CDC25 phosphatases active against human cancer cells
    Brezak, Marie-Christine
    Valette, Annie
    Quaranta, Muriel
    Contour-Galcera, Marie-Odile
    Jullien, Denis
    Lavergne, Olivier
    Frongia, Celine
    Bigg, Dennis
    Kasprzyk, Philip G.
    Prevost, Gregoire Pierre
    Ducommun, Bernard
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (06) : 1449 - 1456
  • [16] Novel synthetic inhibitor of CDC25 phosphatases:: BN82002
    Brezak, MC
    Quaranta, M
    Mondésert, O
    Galcera, MO
    Lavergne, O
    Alby, F
    Cazales, M
    Baldin, W
    Thurieau, C
    Harnett, J
    Lanco, C
    Kasprzyk, PG
    Prevost, GP
    Ducommun, B
    [J]. CANCER RESEARCH, 2004, 64 (09) : 3320 - 3325
  • [17] Redox regulation of Cdc25B by cell-active quinolinediones
    Brisson, M
    Nguyen, T
    Wipf, P
    Joo, B
    Day, BW
    Skoko, JS
    Schreiber, EM
    Foster, C
    Bansal, P
    Lazo, JS
    [J]. MOLECULAR PHARMACOLOGY, 2005, 68 (06) : 1810 - 1820
  • [18] Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase
    Brisson, M
    Nguyen, T
    Vogt, A
    Yalowich, J
    Giorgianni, A
    Tobi, D
    Bahar, I
    Stephenson, CRJ
    Wipf, P
    Lazo, JS
    [J]. MOLECULAR PHARMACOLOGY, 2004, 66 (04) : 824 - 833
  • [19] Role of the Cdc25A phosphatase in human breast cancer
    Cangi, MG
    Cukor, B
    Soung, P
    Signoretti, S
    Moreira, G
    Ranashinge, M
    Cady, B
    Pagano, M
    Loda, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) : 753 - 761
  • [20] Regulation of MAP kinases by the VHR dual-specific phosphatase - Implications for cell growth and differentiation
    Cerignoli, Fabio
    Rahmouni, Souad
    Ronai, Ze'ev
    Mustelin, Tomas
    [J]. CELL CYCLE, 2006, 5 (19) : 2210 - 2215